We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+0.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4B
AUM Growth
+$261M
(+7%)
Cap. Flow
+$281M
Cap. Flow
% of AUM
7.02%
Top 10 Holdings %
Top 10 Hldgs %
19.74%
Holding
679
New
127
Increased
246
Reduced
223
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$104M |
| 2 |
Apple
AAPL
|
+$60.7M |
| 3 |
Amazon
AMZN
|
+$47.5M |
| 4 |
American Express
AXP
|
+$28.7M |
| 5 |
Travelers Companies
TRV
|
+$27.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Solar
FSLR
|
+$28.1M |
| 2 |
Johnson & Johnson
JNJ
|
+$28.1M |
| 3 |
Clorox
CLX
|
+$26.2M |
| 4 |
TJX Companies
TJX
|
+$24.8M |
| 5 |
McKesson
MCK
|
+$23.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.39% |
| 2 | Financials | 11.87% |
| 3 | Technology | 10.68% |
| 4 | Communication Services | 10.67% |
| 5 | Consumer Discretionary | 9.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TTPH
376
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.31M | 0.03% |
14,200
+3,520
| +33% | +$352K |
|
377
Dominion Energy
D
$62.5B
| $1.28M | 0.03% |
17,131
-73,810
| -81% | -$5.22M |
|
378
VF Corp
VFC
$6.68B
| $1.28M | 0.03% |
21,107
+2,455
| +13% | +$143K |
|
|
PXD
379
DELISTED
Pioneer Natural Resource Co.
PXD
| $1.28M | 0.03% |
9,136
+1,723
| +23% | +$214K |
|
380
PACCAR
PCAR
$69.6B
| $1.26M | 0.03% |
34,830
+3,096
| +10% | +$104K |
|
|
PARA
381
DELISTED
Paramount Global Class B
PARA
| $1.26M | 0.03% |
22,992
+2,512
| +12% | +$122K |
|
382
Annaly Capital Management
NLY
$16.9B
| $1.25M | 0.03% |
+30,508
| New | +$1.2M |
|
|
CBIO
383
Crescent Biopharma
CBIO
$602M
| $1.24M | 0.03% |
2,099
-101
| -5% | -$51.8K |
|
384
Intercontinental Exchange
ICE
$82.4B
| $1.24M | 0.03% |
26,425
+3,280
| +14% | +$160K |
|
385
W.W. Grainger
GWW
$65.3B
| $1.23M | 0.03% |
5,301
+556
| +12% | +$116K |
|
|
BNY
386
Bank of New York Mellon
BNY
$108B
| $1.23M | 0.03% |
+33,585
| New | +$1.22M |
|
387
TSMC
TSM
$2.09T
| $1.23M | 0.03% |
+47,000
| New | +$1.1M |
|
|
AVDL
388
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.22M | 0.03% |
111,000
-44,600
| -29% | -$443K |
|
|
GGP
389
DELISTED
GGP Inc.
GGP
| $1.22M | 0.03% |
41,118
+2,497
| +6% | +$68.6K |
|
390
Baxter International
BAX
$11.6B
| $1.21M | 0.03% |
+29,558
| New | +$1.13M |
|
|
SGMO
391
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.2M | 0.03% |
+200,000
| New | +$1.2M |
|
392
Zimmer Biomet
ZBH
$17.7B
| $1.19M | 0.03% |
11,581
-5,554
| -32% | -$537K |
|
393
Applied Materials
AMAT
$426B
| $1.17M | 0.03% |
+55,500
| New | +$1.01M |
|
394
Regency Centers
REG
$15B
| $1.16M | 0.03% |
15,534
+817
| +6% | +$58.4K |
|
395
Rockwell Automation
ROK
$51.4B
| $1.15M | 0.03% |
10,121
-94,328
| -90% | -$9.57M |
|
396
Marathon Petroleum
MPC
$90.3B
| $1.14M | 0.03% |
30,707
+6,370
| +26% | +$242K |
|
|
TCON
397
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $1.13M | 0.03% |
815
-85
| -9% | -$121K |
|
398
Corning
GLW
$126B
| $1.13M | 0.03% |
54,464
-102,767
| -65% | -$1.91M |
|
399
Dollar General
DG
$25.9B
| $1.11M | 0.03% |
13,084
-86,431
| -87% | -$6.54M |
|
|
PX
400
DELISTED
Praxair Inc
PX
| $1.11M | 0.03% |
9,773
-20,382
| -68% | -$2.13M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q1 2016 Portfolio in Review
As of Q1 2016, Candriam SCA held 679 positions worth $4B, up 7% from $3.74B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA deployed $281M of net new capital in Q1 2016, opening 127 new positions and adding to 246 existing holdings. Its largest new stake was Amgen: 700,333 shares worth $104M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 29% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was First Solar, an estimated $28.1M trimmed.
- Candriam SCA's largest Q1 2016 buy was Amgen: 700,333 shares worth $104M.
- Candriam SCA added most to Mead Johnson Nutrition Company in Q1 2016, an estimated $22.2M increase.
- Candriam SCA's biggest Q1 2016 reduction was First Solar, cutting an estimated $28.1M.
- Candriam SCA fully exited Avangrid, Inc. in Q1 2016, selling an estimated $9.6M.
- Candriam SCA's ten largest holdings make up 20% of its $4B portfolio in Q1 2016.
- Candriam SCA opened 127 new positions and closed 43 in Q1 2016.
- Candriam SCA's portfolio value rose 7% quarter-over-quarter to $4B.
Based on Candriam SCA's 13F filing for Q1 2016, filed 27 Apr 2016.